NTT/SAP
15.9.2016 11:13:23 CEST | Business Wire | Press release
SAP SE (NYSE:SAP) and Nippon Telegraph and Telephone Corporation (NTT) (NYSE:NTT) announced today its partnership enhancement in ‘Co-Innovation’, ‘Cross-Selling of Solutions’ and ‘Global Reference’.
SAP and NTT are collaborating by integrating cutting-edge technologies. As the first project of this initiative, to support safety operation of the transportation industry, the two companies have developed a solution combining SAP’s Connected Transportation Safety (CTS) solutions, which collects and analyzes vehicle related data, with NTT’s hitoe®, sensing fabric jointly developed with Toray Industries, and NTT IoT analytics platform, which provides driver’s biological data including heart rate and mental fatigue estimate, the project aims to provide more accurate and real-time information about vehicle and driver’s condition.
In cooperation with Keifuku Bus Co., Ltd (Fukui, Japan), SAP and NTT Group will conduct a field trial from October 2016, targeting to provide service from January 2017. The companies are planning to rollout this solution in the United States and Europe as well.
“We are honored to partner with NTT group who runs the world’s biggest data centers,” said Rob Enslin, member of the Executive Board of SAP SE and president of Global Customer Operations, SAP. “This partnership brings significant impact on SAP to broaden customers’ choice upon facilitating digital transformation. The integration of NTT’s cutting-edge technologies and SAP’s revolutionary solutions will generate momentum to elevate the overall market to the next level. By closely collaborating on a global scale, NTT and SAP will continuously strengthen ties to drive the three key initiatives including Co-innovation, Global Partnership, and SAP Solution Reference Customer in a long term perspective.”
“NTT aims to contribute to business transformation of its enterprise clients by providing high value-added services with partners.” said Jun Sawada, Senior Executive Vice President of NTT, “Global partnership with SAP is a significant step for strengthening our competitiveness in the rapidly changing ICT market. Through this partnership, along with SAP’s expertise and experiences, NTT can enhance its capabilities to support our global clients, and can accelerate digital transformation of industries.”
This co-innovation effort started in Palo Alto, California and has been led by NTT Labs and SAP Labs China. SAP and NTT Group intend to continue co-innovations in various areas with new technologies and expand its partnership through marketing promotion globally.
SAP and NTT Group have agreed to advance their digital practice collaboration and have formatted a new partner for Industrial Revolution. Primary target for 2016 is to move customers to the cloud for IoT and Industry 4.0.
While the partnership is not limited to Industrial Revolution, both companies are also accelerating their collaboration around private managed cloud solutions such as SAP HANA Enterprise Cloud leveraging NTT’s world class data center network around the globe. NTT is also a S/4 HANA Adoption Pinnacle Award Winner 2016.
In addition, NTT and SAP will create a global reference which could become a universal model. NTT has been working on establishing business platform as well as IT infrastructure to create synergy within the group. To accelerate the process, NTT is going to utilize the latest SAP solutions.
About SAP
As market leader in enterprise application software, SAP (NYSE: SAP) helps companies of all sizes and industries run better. From back office to boardroom, warehouse to storefront, desktop to mobile device – SAP empowers people and organizations to work together more efficiently and use business insight more effectively to stay ahead of the competition. SAP applications and services enable more than 320,000 customers to operate profitably, adapt continuously, and grow sustainably. The company is traded under the ‘SAP’ brand on the Frankfurt Stock Exchange, the New York Stock Exchange and other major global bourses. For more information, visit www.sap.com .
Copyright© 2016 SAP SE or an SAP affiliate company. All rights reserved.
SAP,
the SAP logo and other SAP products and services mentioned herein as
well as their respective logos are trademarks or registered trademarks
of SAP SE (or an SAP affiliate company) in Germany and other countries.
Other company names, logos, product names, etc. mentioned herein are the
registered trademarks or trademarks of the companies in question.
About Nippon Telegraph and Telephone Corporation (NTT)
NTT Group delivers advanced technology and innovative solutions in
networking, software communications, and cloud computing that help
transform businesses, governments and societies around the world.
NTT
Group will deliver convenient, enriched and reliable services to support
customers as a ‘Value Partner’ that its customers will continue to
select. Today, 85% of Fortune Global 100 companies rely on NTT Group as
their business partner. NTT Group generates over $95 billion in annual
revenues, has over 240 data centers and employs more than 241,000
professionals working in 87 countries. For more information, visit www.ntt-global.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160915005612/en/
Contact:
Media Contacts
SAP Global PR
contact
Jason Loesche
j.loesche@sap.com
or
SAP
Japan Co., Ltd.
Kaori Suzuki, +81-(3) 6737-3880 (division
switchboard); +81-80-1007-5933 (direct line)
Public Relations
kaori.suzuki@sap.com
or
Nippon
Telegraph and Telephone Corporation
Public Relations Office
ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
